Aflac Set to Release Q2 Earnings Amid Analyst Predictions
Aflac (NYSE: AFL) is expected to announce its Q2 earnings results on August 5, 2025, following the market close. Analysts anticipate that the company will report earnings of $1.73 per share and revenue of approximately $4.30 billion for the quarter. This announcement comes at a time when Aflac’s stock has shown a slight decline, opening at $98.10 on Monday.
The company currently boasts a market capitalization of $53.04 billion. Aflac’s price-to-earnings ratio stands at 15.33, and its PEG ratio is 3.03. The stock has a beta of 0.83, indicating a lower volatility compared to the broader market. Additionally, Aflac’s 50-day simple moving average is $102.58, while the 200-day average is $105.05. Over the past year, the stock has fluctuated between a low of $95.97 and a high of $115.50.
Recent Insider Transactions and Analyst Ratings
In recent trading activity, insider transactions have drawn attention. On May 8, Director Joseph L. Moskowitz sold 1,000 shares at an average price of $106.79, resulting in a total transaction of $106,790.00. Following this sale, Moskowitz holds 26,096 shares valued at approximately $2.79 million, reflecting a 3.69% decrease in his ownership.
Similarly, on May 15, Director Arthur Reginald Collins sold 2,750 shares at an average price of $105.70, totaling $290,675.00. After this transaction, Collins owns 6,728 shares, valued at around $711,149.60, marking a 29.01% decrease in his stake. In total, insiders have sold 40,750 shares of Aflac stock worth $4,304,295 in the last quarter, with corporate insiders now owning 0.80% of the company’s stock.
Analysts have been active in their evaluations of Aflac. Barclays has set a price target of $98.00 and assigned an “underweight” rating. In contrast, JPMorgan Chase & Co. raised its price target from $96.00 to $100.00, maintaining a “neutral” rating. Keefe, Bruyette & Woods increased its target from $104.00 to $106.00 with a “market perform” rating. Meanwhile, Raymond James Financial adjusted its price objective from $115.00 to $110.00 while maintaining an “outperform” rating.
As of now, three analysts have rated Aflac with a sell recommendation, eight with a hold rating, and three have given it a buy rating. According to data from MarketBeat.com, Aflac holds an average rating of “Hold” with a consensus target price of $108.15.
Aflac’s Business Overview
Aflac Incorporated, through its subsidiaries, specializes in providing supplemental health and life insurance products. The company operates in two main segments—Aflac Japan and Aflac U.S. The Aflac Japan segment offers a variety of insurance products, including cancer, medical, and nursing care insurance, as well as work leave and whole life policies.
As Aflac prepares for its earnings announcement, stakeholders will closely monitor the results and any insights provided by company executives regarding future growth and market conditions. The outcomes may shape investor sentiment and influence stock performance in the days to follow.
